![PharmiWeb](https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/921/normal/Screen_Shot_2018-09-17_at_18.39.39.png?1537206114)
Investigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress1
PharmiWeb,
Atlanta, Georgia (US), 12 June 2022 – Today, Novo Nordisk announced results of once-weekly Sogroya® (somapacitan) injection in…